Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Nutranomics Inc.
DRAPER, Utah, Dec. 19, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to report that the Company has received a product reorder from Buildmore Enterprise Co, Ltd. ("Buildmore"), a health food supplement contract manufacturing and distribution company located in Taipei City, Taiwan.
This latest product reorder for 100 kilograms of Nutranomics' AES (Assimilation Enhancing System) is a follow-up to Buildmore's previous AES order received in late-October. AES is a patented proprietary formulation developed by Nutranomics founder and CEO, Dr. Tracy K. Gibbs, which is expected to be incorporated into existing Buildmore dietary supplements to enhance their bioavailability and/or absorption.
"Buildmore and our other existing recurring customers continue to appreciate the strategic marketing value of adding our AES formulations to their dietary supplement products," stated Mike Brousseau, Managing Director of Nutranomics. "Not only can AES enhance the overall effectiveness of their products by improving nutrient bioavailability and absorption, but equally as important, AES can also provide our exclusive clients with a significant competitive business advantage over other dietary supplement distributors that do not incorporate the patented Nutranomics formula."
Nutranomics Inc. was founded in 1997 by renowned dietary supplement and pharmacognosy expert, Dr. Tracy K. Gibbs. Throughout his career, Dr. Gibbs has dedicated his research to the development of new drugs, treatments, and dietary food supplements derived exclusively from natural sources. Dr. Gibbs has utilized his extensive knowledge of both modern pharmacology and traditional Asian medicine to formulate 100's of dietary supplements and skin care products for various manufacturers and distributors. Dr. Gibbs is the holder of United States patent #7,235,390 B2 "Nutrient Absorption Enhancing Composition and Methods" which Nutranomics has branded and markets as AES (Assimilation Enhancing System). Dr. Gibbs regularly lectures at global symposiums and has authored several books on the subject of health and nutrition, including "Enzyme Power: Heal, Build, and Restore Health (2008)", "My Home Pharmacy: How Foods and Herbs Can Be Your Medicine (2012)", and "Your Guide to Oil of Oregano (2013)". Dr. Gibbs studied chemistry, hematology and botanical medicine in Japan from 1991-1993. In 2004, he was awarded a PhD in Botanical Medicine (Kampo Igaku) from Kenchi (Health Knowledge) Kenkyu (Research) Gakkuin (Graduate School) in Nagoya, Japan, following three years as a lecturing professor at the school. Dr. Gibbs is a former chairman of the International Health Food Research Foundation in Nagoya, Japan, and a current member of the American Society of Pharmacognocy.
Nutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia.
For further information regarding Nutranomics, Inc., please contact our investor relations representatives at firstname.lastname@example.org or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include the Company's expectation of future purchase orders from Buildmore or others. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
©2012 PR Newswire. All Rights Reserved.